CDMO Recipharm has announced an investment of $450,000 for installation of a Proveris Scientific SprayView Measurement System at its facility in Research Triangle Park, North Carolina. The company described the SprayView system as “an important tool that can visualize changes in other critical quality attributes (CQAs) of inhaled and nasal products” and said that it has installed the system next to other inhalation testing equipment and an MDI/DPI pilot process lab.
Recipharm Director of Inhalation Science and Product Development Lei Mao commented, “By employing the SprayView system and expanding our expertise in this technique, we are strengthening our capabilities in inhalation and nasal product development and manufacturing. Inhalation products are extremely complex to develop and manufacture and it is important to understand potential interactions between the formulation and the delivery device throughout the development stages.”
“Acquiring a Sprayview system,” he continued, “has allowed our development team to successfully characterize a nasal spray product currently under development. In addition, our expertise in this technique adds new services for our innovator and generics customers who are coming to us for inhalation and nasal product development, as well as for standalone SprayView analysis.”
In May 2019, Recipharm launched an integrated OINDP services program called Recipharm Inhalation Solutions for development of MDIs, DPIs, and nasal sprays through to scale up and commercial manufacturing. The company also recently announced the acquisition of Consort Medical, including its subsidiaries CDMO Aesica and device manufacturer Bespak, expanding its OINDP capabilities even further.
Read the Recipharm press release.
